Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide eye drops for central serous chorioretinopathy
IRCT20180703040323N1Phase 2Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of dorzolamide in Central Serous Chorioretinopathy (CSCR) (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Risk factors of central serous chorioretinopathy and Efficacy of dorzolamide eye drops. Started Dec 2015; status: completed.
02
Drugs
dorzolamide
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on IRCT20180703040323N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180703040323N1.